Publications
Detailed Information
Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma Suggestion for an Effective Screening Strategy for These Tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Chung, Doo Hyun | - |
dc.contributor.author | Kim, Young-Whan | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Kim, Woo-Ho | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2020-04-27T11:36:50Z | - |
dc.date.available | 2020-04-27T11:36:50Z | - |
dc.date.created | 2020-02-19 | - |
dc.date.issued | 2011-05 | - |
dc.identifier.citation | Journal of Thoracic Oncology, Vol.6 No.5, pp.905-912 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.other | 91834 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165530 | - |
dc.description.abstract | Introduction: The purpose of this study was to analyze the clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase (ALK)-positive advanced pulmonary adenocarcinoma and to devise an effective screening strategy to identify such patients. Methods: We screened advanced pulmonary adenocarcinoma patients to identify ALK-positive cases. The presence of ALK rearrangements was confirmed by fluorescence in situ hybridization. Results: Of the 221 screened patients, 45 demonstrated ALK rearrangements, and these individuals were younger than the ALK-negative patients (p < 0.001). The proportion of never smokers and light smokers was found not to differ according to the ALK status (p = 0.537). Epidermal growth factor receptor (EGFR) mutations and ALK rearrangements were found to be mutually exclusive. Thyroid-transcription factor-1 (TTF-1) expression was observed in all ALK-positive tumors for which immunohistochemistry data were available. The objective response rate and progression-free survival to first-line platinum-based chemotherapy showed no significant differences between ALK-positive and ALK-negative patients. On the other hand, no patient with ALK-positive tumors achieved objective tumor responses to EGFR tyrosine kinase inhibitors (TKIs). ALK rearrangements were not found among individuals who had EGFR mutations, an objective response to a previous EGFR TKI treatment or TTF-1-negative tumors. Conclusion: The clinical outcomes of platinum-based chemotherapy were found not to differ according to the ALK status. Both smokers and never/light smokers should be candidates for ALK screening. We suggest that the exclusion of patients with activating EGFR mutations, an objective response to previous EGFR TKIs, or TTF-1-negative tumors from ALK screening could be an effective enrichment strategy for ALK-positive cases. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier Inc. | - |
dc.title | Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma Suggestion for an Effective Screening Strategy for These Tumors | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1097/JTO.0b013e3182111461 | - |
dc.citation.journaltitle | Journal of Thoracic Oncology | - |
dc.identifier.wosid | 000289554100010 | - |
dc.identifier.scopusid | 2-s2.0-79955482290 | - |
dc.citation.endpage | 912 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | 905 | - |
dc.citation.volume | 6 | - |
dc.identifier.sci | 000289554100010 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Jeon, Yoon Kyung | - |
dc.contributor.affiliatedAuthor | Chung, Doo Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Young-Whan | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Kim, Woo-Ho | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | EML4-ALK FUSION GENE | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | FEATURES | - |
dc.subject.keywordPlus | RARE | - |
dc.subject.keywordAuthor | Lung | - |
dc.subject.keywordAuthor | Adenocarcinoma | - |
dc.subject.keywordAuthor | ALK | - |
dc.subject.keywordAuthor | EGFR | - |
dc.subject.keywordAuthor | TTF-1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.